RVPH Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 114161 min ago

@ $4.65

Išleistas: 13 vas. 2024 @ 19:23

Grąža: -31.61%

Ankstesnis signalas: vas. 13 - 16:32

Ankstesnis signalas: Pardavimas

Grąža: 4.26 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	87 090.00
Vidutinė apimtis	262 906
Rinkos kapitalizacija	88.78M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $-0.280 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.930
ATR14	$0.00800 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Saxena Parag	Buy	585 366	Pre-Funded Warrant
2023-11-20	Saxena Parag	Buy	585 366	Common Stock Warrant (right to buy)
2023-11-13	Funtleyder Leslie D.	Buy	8 200	Stock Option (right to buy)
2023-11-13	Patel Purav	Buy	8 200	Stock Option (right to buy)
2023-11-13	Saxena Parag	Buy	8 200	Stock Option (right to buy)

INSIDER POWER
100.00
Last 72 transactions
Buy: 9 383 157 \| Sell: 2 515 186

Tūris Koreliacija

Ilgas: -0.05 (neutral)

Trumpas: 0.90 (strong)

Signal:(58.114) Same movement expected

Reviva Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos
ISNS	-0.839
APOP	-0.832

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Reviva Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.71
( moderate negative )

-0.72
( moderate negative )

0.00
( neutral )

-0.68
( moderate negative )

0.24
( neutral )

0.86
( strong )

Reviva Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.250

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.250

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.662

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.